secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001618835-22-000204
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem cuts 45 jobs, suspends FY2022 guidance to conserve cash
--------------------------------------------------------------

- Board approved reduction in force of 45 employees; completion expected by end of November 2022.
- Annualized future cost savings estimated at ~$11 million from the workforce reduction.
- Pre-tax charges of ~$0.7 million in Q4 2022 for severance and employee benefits.
- Company suspends prior fiscal year 2022 guidance due to restructuring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000161883522000204/0001618835-22-000204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000161883522000204/evfm-20221101.htm
  HTML page:      https://secwatch.observer/filing/0001618835-22-000204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer